Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Palmitoylated prolactin-releasing peptide treatment had neuroprotective but not anti-obesity effect in fa/fa rats with leptin signaling disturbances

L. Mráziková, S. Hojná, A. Pačesová, L. Hrubá, V. Strnadová, B. Neprašová, B. Železná, J. Kuneš, L. Maletínská

. 2022 ; 12 (1) : 26. [pub] 20220519

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

BACKGROUND/OBJECTIVE: Anorexigenic palmitoylated prolactin-releasing peptide (palm11-PrRP) is able to act centrally after peripheral administration in rat and mouse models of obesity, type 2 diabetes mellitus and/or neurodegeneration. Functional leptin and intact leptin signaling pathways are necessary for the body weight reducing and glucose tolerance improving effect of palm11-PrRP. We have previously shown that palm11-PrRP31 had glucose-lowering properties but not anti-obesity effect in Koletsky rats with leptin signaling disturbances, so improvements in glucose metabolism appear to be completely independent of leptin signaling. The purpose of this study was to describe relationship between metabolic and neurodegenerative pathologies and explore if palm11-PrRP31 could ameliorate them in obese fa/fa rat model with leptin signaling disruption. SUBJECT/METHODS: The fa/fa rats and their age-matched lean controls at the age 32 weeks were used for this study. The rats were infused for 2 months with saline or palm11-PrRP31 (n = 7-8 per group) at a dose of 5 mg/kg per day using Alzet osmotic pumps. During the dosing period food intake and body weight were monitored. At the end of experiment the oral glucose tolerance test was performed; plasma and tissue samples were collected and arterial blood pressure was measured. Then, markers of leptin and insulin signaling, Tau phosphorylation, neuroinflammation, and synaptogenesis were measured by western blotting and immunohistochemistry. RESULTS: Fa/fa rats developed obesity, mild glucose intolerance, and peripheral insulin resistance but not hypertension while palm11-PrRP31 treatment neither lowered body weight nor attenuated glucose tolerance but ameliorated leptin and insulin signaling and synaptogenesis in hippocampus. CONCLUSION: We demonstrated that palm11-PrRP31 had neuroprotective features without anti-obesity and glucose lowering effects in fa/fa rats. This data suggest that this analog has the potential to exert neuroprotective effect despite of leptin signaling disturbances in this rat model.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018365
003      
CZ-PrNML
005      
20250924094417.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41387-022-00205-3 $2 doi
035    __
$a (PubMed)35589696
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Mráziková, Lucia $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0307846
245    10
$a Palmitoylated prolactin-releasing peptide treatment had neuroprotective but not anti-obesity effect in fa/fa rats with leptin signaling disturbances / $c L. Mráziková, S. Hojná, A. Pačesová, L. Hrubá, V. Strnadová, B. Neprašová, B. Železná, J. Kuneš, L. Maletínská
520    9_
$a BACKGROUND/OBJECTIVE: Anorexigenic palmitoylated prolactin-releasing peptide (palm11-PrRP) is able to act centrally after peripheral administration in rat and mouse models of obesity, type 2 diabetes mellitus and/or neurodegeneration. Functional leptin and intact leptin signaling pathways are necessary for the body weight reducing and glucose tolerance improving effect of palm11-PrRP. We have previously shown that palm11-PrRP31 had glucose-lowering properties but not anti-obesity effect in Koletsky rats with leptin signaling disturbances, so improvements in glucose metabolism appear to be completely independent of leptin signaling. The purpose of this study was to describe relationship between metabolic and neurodegenerative pathologies and explore if palm11-PrRP31 could ameliorate them in obese fa/fa rat model with leptin signaling disruption. SUBJECT/METHODS: The fa/fa rats and their age-matched lean controls at the age 32 weeks were used for this study. The rats were infused for 2 months with saline or palm11-PrRP31 (n = 7-8 per group) at a dose of 5 mg/kg per day using Alzet osmotic pumps. During the dosing period food intake and body weight were monitored. At the end of experiment the oral glucose tolerance test was performed; plasma and tissue samples were collected and arterial blood pressure was measured. Then, markers of leptin and insulin signaling, Tau phosphorylation, neuroinflammation, and synaptogenesis were measured by western blotting and immunohistochemistry. RESULTS: Fa/fa rats developed obesity, mild glucose intolerance, and peripheral insulin resistance but not hypertension while palm11-PrRP31 treatment neither lowered body weight nor attenuated glucose tolerance but ameliorated leptin and insulin signaling and synaptogenesis in hippocampus. CONCLUSION: We demonstrated that palm11-PrRP31 had neuroprotective features without anti-obesity and glucose lowering effects in fa/fa rats. This data suggest that this analog has the potential to exert neuroprotective effect despite of leptin signaling disturbances in this rat model.
650    _2
$a zvířata $7 D000818
650    _2
$a tělesná hmotnost $7 D001835
650    12
$a diabetes mellitus 2. typu $x farmakoterapie $7 D003924
650    _2
$a glukosa $7 D005947
650    _2
$a inzulin $x terapeutické užití $7 D007328
650    12
$a leptin $7 D020738
650    _2
$a myši $7 D051379
650    _2
$a obezita $x metabolismus $7 D009765
650    _2
$a hormon uvolňující prolaktin $x farmakologie $x terapeutické užití $7 D056690
650    _2
$a krysa rodu Rattus $7 D051381
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hojná, Silvie $u Institute of Physiology CAS, Prague, Czech Republic
700    1_
$a Pačesová, Andrea $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic
700    1_
$a Hrubá, Lucie $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic
700    1_
$a Strnadová, Veronika $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic
700    1_
$a Neprašová, Barbora $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic $u Institute of Physiology CAS, Prague, Czech Republic $7 xx0335496
700    1_
$a Železná, Blanka $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic
700    1_
$a Kuneš, Jaroslav $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic $u Institute of Physiology CAS, Prague, Czech Republic
700    1_
$a Maletínská, Lenka $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic. maletin@uochb.cas.cz $1 https://orcid.org/0000000342998983
773    0_
$w MED00181736 $t Nutrition & diabetes $x 2044-4052 $g Roč. 12, č. 1 (2022), s. 26
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35589696 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20250924094412 $b ABA008
999    __
$a ok $b bmc $g 1822116 $s 1169608
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 12 $c 1 $d 26 $e 20220519 $i 2044-4052 $m Nutrition & diabetes $n Nutr Diabetes $x MED00181736
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...